NCT01664182 - Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

December 7, 2020

Study Completion Date

December 7, 2020

Conditions

Advanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Pazopanib Hydrochloride

Given PO

DRUG

Sorafenib Tosylate

Given PO

DRUG

Sunitinib Malate

Given PO

BIOLOGICAL

Trebananib

Given IV

Trial Locations (12)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

23116

VCU Massey Cancer Center at Hanover Medical Park, Mechanicsville

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

48201

Wayne State University/Karmanos Cancer Institute, Detroit

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55905

Mayo Clinic in Rochester, Rochester

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH